

Restless Legs Syndrome in Patients with Irritable Bowel Syndrome: Response to Small Intestinal Bacterial Overgrowth Therapy

Leonard B. Weinstock, MD*†; Steve E. Fern, DO†; Stephen P. Duntley, MD*
From *Washington University School of Medicine, St. Louis, Missouri, USA;
†Specialists in Gastroenterology, St. Louis, Missouri, USA.

Digestive Diseases Science May 2008

Partial funding provided by grant from Salix Pharmaceuticals, Inc.
Leonard B. Weinstock, MD, 11525 Olde Cabin Road, St. Louis, MO 63141
Telephone: 314-997-0554, Fax: 314-997-5086, E-mail: lw@giddoctor.net

ABSTRACT

Background: Small intestinal bacterial overgrowth (SIBO) occurs in irritable bowel syndrome (IBS) and fibromyalgia. Since restless legs syndrome (RLS) occurs with fibromyalgia, a link between IBS, SIBO, and RLS was studied.

Methods: IBS patients with abnormal lactulose breath tests received rifaximin 1200 mg/d/10-days, followed by tegaserod 3 mg/long-term, and 1 month of zinc 220 mg/d and once-daily probiotic (N=11) or rifaximin monotherapy (N=2). IBS symptom improvement was assessed after Rifaximin. RLS symptoms, IBS symptoms, and overall IBS global improvement were assessed at last posttreatment visit: 8/10 patients were followed long-term (mean, 139 days; range, 54–450 days).

Results: Ten of 13 patients exhibited $\geq 80\%$ improvement from baseline in RLS symptoms. Five maintained complete resolution of RLS symptoms. Global gastrointestinal symptom improvement was great (n=6), moderate (n=5), or mild (n=2).

Conclusion: This study suggests that SIBO associated with IBS may be a factor in some RLS patients and SIBO therapy provides long-term RLS improvement.

INTRODUCTION

Restless legs syndrome (RLS) is characterized by an urge for leg movement, often with abnormal leg sensations. Symptoms are triggered by rest, often at night, and improve temporarily with movement, especially walking. This syndrome has a prevalence ranging from 7% to 15% and significantly contributes to sleep disorders (1–3). Most RLS cases are idiopathic, but contributing factors include iron deficiency and renal failure (4, 5). Restless legs syndrome occurs frequently in patients with peripheral neuropathy, particularly in individuals with Charcot-Marie-Tooth disease (6,7). The prevalence of RLS has also been reported in a single case series of fibromyalgia (31% of 135 patients)(8) and scleroderma (22% of 27 patients)(9).

Fibromyalgia and irritable bowel syndrome (IBS) are accepted as common comorbid conditions (10–12). In the past, central hypersensitivity had been considered a mutual problem (13). However, evidence continues to gather, suggesting that small intestinal bacterial overgrowth (SIBO), with systemic inflammation and visceral neurological changes, may be an alternative explanation for the development and persistence of IBS, fibromyalgia, and other hypersensitivity syndromes (eg, interstitial cystitis and chronic fatigue syndrome) (14–19). The occurrence of SIBO in patients with IBS has been suggested by direct evidence with small bowel culturing and by indirect evidence using breath testing (20–24). One explanation for the occurrence of SIBO in patients with IBS as well as other conditions that involve SIBO is an abnormality of the

phase 3 part of the migrating motor complex (15, 25, 26). Increased intestinal permeability has been observed in patients with postinfectious IBS and diarrhea-predominant IBS (27) and may be a consequence of SIBO (15).

The propositus that led to the current study was a patient with a 14-year history of chronic postprandial abdominal pain and diarrhea that had immediately followed an episode of travelers' diarrhea, with subsequent development of RLS 2 months later. It was suspected that the patient might have postinfectious IBS and SIBO. Empiric treatment with the minimally absorbed (<0.4%), broad-spectrum antibiotic rifaximin resulted in a dramatic, rapid, and prolonged response for both RLS and IBS symptoms. In this open-label, observational pilot trial, the efficacy of rifaximin, followed by treatment for possible motility and permeability disturbance,(28–30) was evaluated in IBS patients with RLS who showed indirect evidence of SIBO.

METHODS

Patient Population

Patients visiting a community-based adult gastroenterology clinic over a 4-month period were eligible for the study if they presented with functional bowel symptoms and had abnormal lactulose breath test (LBT) results. Patients were excluded if they had celiac disease, Crohn's disease, pancreatic insufficiency, ulcerative colitis, scleroderma, diabetes, chronic renal failure, or surgeries predisposing them to SIBO. A diagnosis of RLS was confirmed using the Johns Hopkins validated interview process (31).

Lactulose Breath Testing

Patients consumed a low carbohydrate dinner and fasted overnight. Breath samples were collected every 15 min for 180 min and were analyzed by gas chromatography (QuinTron DP Plus MicroLyzer™, QuinTron Instrument Company, Milwaukee, Wisconsin) for levels of hydrogen and methane. After a baseline recording, patients consumed 10 g of lactulose powder (Kristalose®, Bertek Pharmaceuticals Inc, Sugar Land, Texas) dissolved in 240 ml of water. An abnormal LBT result was defined as an increase of >20 ppm above baseline levels for hydrogen and/or methane gas ≤180 minutes after ingesting lactulose. An abnormal flatline LBT result was defined as a lack of a >5-ppm increase above baseline levels for either hydrogen or methane during the 180-min test. The flat line response is suggestive of bacterial overgrowth by hydrogen sulfide producing bacteria and which is not detectable by current gas chromatography technology (personal communication, Henry C. Lin, MD 2005).

Treatment

Patients received rifaximin (Xifaxan®, Salix Pharmaceuticals, Inc, Morrisville, North Carolina) 400 mg 3 times daily for 10 days. This was followed by long-term administration of the prokinetic medicine tegaserod (Zelnorm®, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) 3 mg nightly plus short-term treatment with zinc 220 mg/d for 1 month for increased small intestinal permeability and a bifidobacteria-based probiotic (Flora-Q®, Kenwood Therapeutics, Fairfield, New Jersey) once daily for 1 month. Patients may have also received rifaximin alone (n = 2).

Patient Evaluation and Follow-up

Each patient completed a questionnaire identifying the occurrence and rating the severity of 6 IBS symptoms experienced during the week before the LBT was conducted (baseline): abdominal pain, bloating, constipation, diarrhea, flatulence, and postprandial fullness. A history consistent with RLS and fibromyalgia was sought. Serum ferritin levels

were measured at baseline. The ferritin was measured owing to the frequent occurrence of peripheral and central iron deficiency in RLS (1,4).

Each patient received a follow-up questionnaire by mail and was asked to report on each of the gastrointestinal (GI) symptoms originally reported to be present at baseline as well as the percentage of improvement immediately after completing rifaximin treatment (day 11) and at the end of follow-up. Patients rated overall GI symptom improvement at the last follow-up visit as greatly improved, moderately improved, mildly improved, or no improvement. The percentage of RLS symptom improvement was assessed at the end of follow-up.

RESULTS

Thirteen IBS patients with confirmed RLS were included in the study. Eleven of these 13 patients were originally included in a SIBO study of IBS (24): 19 of 161 patients with an abnormal LBT result thought they had RLS. A diagnosis of RLS was confirmed in 11 of these 19 patients by the Johns Hopkins validated interview process. The remaining 2 of 13 patients (1 was the propositus and 1 was referred from the neurology clinic) had been previously evaluated and treated for RLS by a neurologist.

All 12 patients who were tested for SIBO had an abnormal LBT result (Table 1). The propositus was treated empirically. Most of these 12 patients (75%) were diagnosed with high-hydrogen levels. One of these patients had a flatline LBT result. This result suggested the possibility of overgrowth of hydrogen sulfide-producing bacteria in the small intestine, which is not detectable by current LBT technology (Henry C. Lin, MD; October 9, 2006, personal communication). The most common GI symptoms at baseline included abdominal pain (n = 13), bloating (n = 13), diarrhea (n = 11), and constipation (n = 9) (Table 1).

Eleven patients were treated with rifaximin 1200 mg/d for 10 days, followed by treatment with a prokinetic, zinc for intestinal permeability, and probiotic therapy. The remaining 2 patients (neurology clinic patient and propositus) received a modified treatment regimen. The neurology patient was treated with rifaximin 400 mg 3 times daily for 10 days. The propositus was treated empirically (prior to LBT availability at the clinic) and received rifaximin 400 mg 3 times daily for 10 days and a second course of the same regimen 2 months posttreatment. Two months after completion of the second course, the patient was prescribed rifaximin 800 mg/d for 12 months.

Only 3 of 13 patients were diagnosed with possible iron deficiency at baseline. The neurology patient had borderline iron deficiency (ferritin level, 12 ng/dL; normal, <10 ng/dL) and received concomitant long-term iron supplementation (ferrous sulfate 325 mg 3 times daily). One additional patient with borderline normal levels of ferritin and one patient with low ferritin levels did not receive iron supplementation during SIBO therapy.

Percentages of RLS and IBS symptom improvement as well as global IBS symptom improvement were assessed at a mean of 107 days (range, 22–450 days). Ten of 13 patients with RLS exhibited $\geq 80\%$ improvement in RLS symptoms at the last follow-up visit. The 10 patients who responded included the 3 patients who had borderline or low serum levels of iron at baseline. All 10 patients indicated that the $\geq 80\%$ improvement in RLS symptoms occurred during or at the end of rifaximin treatment. Eight of the 10 patients with $\geq 80\%$ improvement in RLS symptoms were followed long-term (mean, 139 days; range, 54–450 days), and 5 of the 8 patients reported complete (100%) resolution of RLS symptoms at the last follow-up visit (Table 2).

After completion of 10 days of rifaximin therapy (day 11), GI symptom improvement was reported as follows: abdominal pain (74%), diarrhea (73%), bloating (70%), postprandial fullness (65%), constipation (64%), and flatulence (47%). At the end

of follow-up, symptom improvement was maintained: abdominal pain (81%), diarrhea (68%), bloating (76%), postprandial fullness (67%), constipation (59%), and flatulence (55%). Global symptom improvement was rated as greatly improved for 6 patients, moderately improved for 5 patients, and mildly improved for 2 patients. Follow-up LBT was not available for the 13 patients, with the exception of the neurology patient. This individual had a normal LBT result 2 months after completing rifaximin therapy.

DISCUSSION

Substantial overlap exists between IBS and other hypersensitivity disorders (32). Small intestinal bacterial overgrowth may be a common denominator for these disorders, which are characterized by visceral hypersensitivity, chronic inflammation, and neurochemical changes (15). Altered genetic control of immune activation, production of proinflammatory cytokines, increased intestinal permeability, and immune responses triggered by bacterial endotoxins may lead to the development of intestinal and extraintestinal manifestations of IBS (15–17, 33–35). Persistence of an underlying motility disorder of the migrating motor complex is thought to be responsible for SIBO and GI symptom relapse after antibiotic therapy (15, 25).

It was hypothesized that a relationship might exist between RLS, IBS, and SIBO because RLS may be a comorbid condition of fibromyalgia,(8) fibromyalgia is a known comorbid condition of IBS,(10–12) and fibromyalgia and IBS have been associated with SIBO (14). Also, there was a dramatic response to rifaximin by the propositus who had postinfectious IBS, which is caused by SIBO. Evidence that SIBO plays a role in IBS continues to accumulate despite continued debate and controversy (14, 15, 21–24, 36, 37). In a single case series, patients with scleroderma had an increased incidence of RLS, although they did not have end-stage small intestinal disease with the commonly accepted presentation of SIBO, such as malabsorption and steatorrhea (9). Another possible mechanism to explain a role for SIBO in RLS is that a chronic inflammatory state directly (38) and indirectly (via increasing hepcidin levels)(39) plays a role in iron deficiency,(4) which is sometimes associated with RLS. Iron deficiency can affect cell oxygenation by direct (eg, reduced hemoglobin levels) and indirect mechanisms (eg, functioning of mitochondrial iron-containing proteins required to process oxygen in cells) (40). We theorize that the latter may be one mechanism to explain RLS muscle discomfort that is relieved by leg movement.

This pilot study provides preliminary data to support the novel hypotheses that SIBO associated with IBS may be an important factor in some patients with RLS and that comprehensive SIBO therapy may provide long-term improvement in both RLS and GI symptoms. The limitations of this study include the open-label study design, the multiple medication protocol, the lack of a placebo arm, posttreatment LBT performed in only 1 patient, and not using the International RLS Study Group Scale. A randomized, double-blind, placebo-controlled study of rifaximin is planned to determine the relationships among SIBO, RLS, and IBS by performing an LBT and measuring interleukin 6 levels, hepcidin levels, Likert scale GI scores, IBS quality of life scores, and ratings on the International RLS Study Group Scale, pretreatment and posttreatment. If SIBO is a potential trigger, then the treatment paradigm for RLS could radically change for this difficult-to-treat, common disorder.

*Table 1. Patient Demographics and Baseline Characteristics (n = 13)	
Male:female, n	2:11
Mean age, y (range)	50 (35–63)
RLS, n	13
Fibromyalgia, n	6
Serum iron status	
Iron deficiency, n	1
Borderline iron deficiency, n	2
Meeting IBS Rome II criteria, n	13
Baseline GI symptoms, n	
Abdominal pain	13
Bloating	13
Constipation	9
Diarrhea	11
Excessive flatulence	10
Postprandial fullness	11
LBT result	
High hydrogen	9
High methane	2
Flatline	1
Not performed*	1
RLS, restless legs syndrome; IBS, irritable bowel syndrome; GI, gastrointestinal; LBT, lactulose breath test; *Propositus patient.	

Table 2. Percentage Improvement in RLS Symptoms After SIBO Treatment*	
<i>RLS Symptom Improvement</i>	<i>Patients, n (%)</i> <i>n = 13</i>
Improvement, %	
100	6 (46)
95	2 (15)
90	1 (8)
80	1 (8)
50	1 (8)
30	1 (8)
25	1 (8)
Mean overall improvement	82%
Mean overall improvement in 8 patients with long-term follow-up	86%
Mean follow-up, d (range)	139 (54–450)
<p>RLS, restless legs syndrome; SIBO, small intestinal bacterial overgrowth; *SIBO treatment: rifaximin 1200 mg/d for 10 days followed by tegaserod 3 mg long-term and 1 month of zinc 220 mg and probiotic daily. Deviations from this regimen occurred in 2 patients: the propositus had two 10-day courses of 1200 mg/d rifaximin followed by rifaximin 800 mg/d for 1 year; and 1 patient received rifaximin 1200 mg/d for 10 days (these 2 patients reported 100% improvement).</p>	

REFERENCES

1. **Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L.** Restless legs syndrome prevalence and impact: REST general population study. *Arch Intern Med* 2005;165:1286–1292.
2. **Berger K, Luedemann J, Trenkwalder C, John U, Kessler C.** Sex and the risk of restless legs syndrome in the general population. *Arch Intern Med* 2004;164:196–202.
3. **Lavigne GJ, Montplaisir JY.** Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. *Sleep* 1994;17:739–743.
4. **Allen R.** Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). *Sleep Med* 2004;5:385–391.
5. **Gigli GL, Adorati M, Dolso P, Piani A, Valente M, Brotini S, Budai R.** Restless legs syndrome in end-stage renal disease. *Sleep Med* 2004;5:309–315.
6. **Ondo W, Jankovic W.** Restless legs syndrome: clinicoetiologic correlates. *Neurology* 1996;47:1435–1441.
7. **Iannaccone S, Quattrini A, Sferrazza B, Ferini-Strambi L.** Charcot-Marie-Tooth disease type 2 with restless legs syndrome. *Neurology* 2000;54:1013–1014.
8. **Yunus MB, Aldag JC.** Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. *BMJ* 1996;312:1339.
9. **Prado GF, Allen RP, Trevisani VMF, Toscano VG, Earley CJ.** Sleep disruption in systemic sclerosis (scleroderma) patients: clinical and polysomnographic findings. *Sleep Med* 2002;3:341–345.
10. **Veale D, Kavanagh G, Fielding JF, Fitzgerald O.** Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. *Br J Rheumatol* 1991;30:220–222.
11. **Lubrano E, Iovino P, Tremolaterra F, Parsons WJ, Ciacci C, Mazzacca G.** Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder. *Int J Colorectal Dis* 2001;16:211–215.
12. **Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D.** Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. *Am J Gastroenterol* 1999;94:3541–3546.
13. **Chang L, Berman S, Mayer E, Suyenobu B, Derbyshire S, Naliboff B, Vogt B, Fitzgerald L, Mandelkern MA.** Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. *Am J Gastroenterol* 2003;98:1354–1361.
14. **Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC.** A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. *Ann Rheum Dis* 2004;63:450–452.
15. **Lin HC.** Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA* 2004;292:852–858.
16. **van der Veek PPJ, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA.** Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. *Am J Gastroenterol* 2005;100:2510–2516.
17. **Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Bolin TD, Thomas MC.** Mucosal cytokine production in small-intestinal bacterial overgrowth. *Scand J Gastroenterol* 1996;31:977–984.
18. **Barbara G, Stanghellini V, de Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R.** Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004;126:693–702.

19. **Törnblom H, Lindberg G, Nyberg B, Veress B.** Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. *Gastroenterology* 2002;123:1972–1979.
20. **Romagnuolo J, Schiller D, Bailey RJ.** Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. *Am J Gastroenterol* 2002;97:1113–1126.
21. **Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A.** Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. *Aliment Pharmacol Ther* 2005;22:1157–1160.
22. **Pimentel M, Chow EJ, Lin HC.** Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2003;98:412–419.
23. **Pimentel M, Park S, Mirocha J, Kane JMSV, Kong Y.** The Effects of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of irritable bowel syndrome. *Ann Intern Med* 2006;145:557–563.
24. **Weinstock LB, Todorczuk JR, Fern SE, Thyssen, EP.** Comprehensive small intestinal bacterial (SIBO) therapy for irritable bowel syndrome (IBS). *Am J Gastroenterol* 2006;101(Suppl 2):S470–S471.
25. **Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC.** Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. *Dig Dis Sci* 2002;47:2639–2643.
26. **Vantrappen G, Janssens J, Hellemans J, Ghoo Y.** The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. *J Clin Invest* 1977;59:1158–1166.
27. **Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC.** Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. *Am J Gastroenterol* 2006;101:1288–1294.
28. **Plaza MA.** 5-hydroxytryptamine and the gastrointestinal migrating motor complex. *Curr Opin Investig Drugs* 2001;2:539–544.
29. **Sturniolo GC, Fries W, Mazzon E, Di Leo V, Barollo M, D'inca R.** Effect of zinc supplementation on intestinal permeability in experimental colitis. *J Lab Clin Med* 2002;139:311–315.
30. **Quigley EM, Quera R.** Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. *Gastroenterology* 2006;130(Suppl 1):S78-S90.
31. **Hening WA, Allen RP, Thanner S, Washburn T, Heckler D, Walters AS, Earley CJ.** The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. *Sleep Med* 2003;4:137–141.
32. **Aaron LA, Buchwald D.** A review of the evidence for overlap among unexplained clinical conditions. *Ann Intern Med* 2001;134:868–881.
33. **Blackburn-Munro G.** Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. *Curr Pain Headache Rep* 2004;8:116–124.
34. **Bomholt SF, Harbuz MS, Blackburn-Munro G.** Involvement and role of the hypothalamo-pituitary-adrenal (HPA) stress axis in animal models of chronic pain and inflammation. *Stress* 2004;7:1–14.
35. **Grinevich V, Ma X-M, Herman JP, Jezova D, Akmayev I, Aguilera G.** Effect of repeated lipopolysaccharide administration on tissue cytokine expression and

-
- hypothalamic-pituitary-adrenal axis activity in rats. *J Neuroendocrinol* 2001;13:711–723.
36. **Pimentel M, Lin HC.** Response to Dr. Parisi et al. *Am J Gastroenterol* 2003;98:2573–2574.
 37. **Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.** Functional bowel disorders. *Gastroenterology* 2006;130:1480–1491.
 38. **Raja KB, Latunde-Dada GO, Peters TJ, McKie AT, Simpson RJ.** Role of interleukin-6 in hypoxic regulation of intestinal iron absorption. *Br J Haematol* 2005;131:656–662.
 39. **Liu X-B, Nguyen N-BH, Marquess KD, Yang F, Haile DJ.** Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. *Blood Cells Mol Dis* 2005;35: 47–56.
 40. **Alpers DH, Klein S.** Approach to the patient requiring nutritional supplementation. In: Yamada T, Alpers DH, Laine L, et al, editors. *Textbook of gastroenterology*. 2nd ed. Philadelphia: Lippincott, Williams, & Wilkins; 2003. p. 1056–1084.